UK-CAB 70: Ageing, polypharmacy and POPPY study community feedback
Friday 15 November 2019
Programme
| 09.30-09.40 | Arrival, tea and refreshments |
| 09:40-10:00 | Welcome and introductions UK-CAB updates Company pre-meeting |
| 10:00-11:15 | Company meeting: MSD |
| 11.15-11.30 | Break |
| 11.30-12.30 | Polypharmacy – Marta Boffito, Chelsea and Westminster Foundation Hospital |
| 12.45-14.00 | Lunch |
| 14.00-16.30 | POPPY study community feedback – Alan Winston and Caroline Sabin |
| 16.30-16.30 | Break |
| 16.30-17.00 | Members Updates Any other business & reflection |
| 17.00 | Meeting close |
Slides and meeting report
Polypharmacy – Marta Boffitto, Chelsea and Westminster Foundation Hospital
POPPY study slides – to follow
Meeting report to follow
Background reading and videos/webcasts
The POPPY study
https://academic.oup.com/ije/article/47/5/1391/4994261
i-Base reports from the 10th International Workshop on HIV and Ageing
http://i-base.info/htb/36814
Frailty in HIV care and the importance of lifestyle changes
http://i-base.info/htb/36816
The challenges of HIV treatment in an era of polypharmacy
http://www.croiconference.org/sessions/challenges-hiv-treatment-era-polypharmacy
The Next Therapeutic Challenge in HIV: Polypharmacy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715685/
Financial support
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year.
This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering. The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.